In an in vivo mouse model of HNSCC, Bmi-1+ CSCs were enriched in tumors following treatment with Cisplatin and anti-PD-1 therapy, but treatment with the Bmi-1 inhibitor PTC209 prevented induction of these cells and tumor progression (119). Here, BMI1 is linked to head and neck squamous cell carcinoma.